Table 3.

Patient clinical characteristics

Patient ID no.Infused VSTsHLA matchingViral diseaseReduction in immuno-suppressionPrior antiviral(s)Duration prior antiviral therapyAntiviral drug intoleranceCMV resistanceChange in antiviral post-VSTResponse by 6 wkOverall outcome
3910 C6790 2/8 No No Ganciclovir 17 No No No CR Sustained CR 
3944 C6798 4/8 No No Leflunomide 94 AKI, cytopenia Yes No CR Sustained CR 
3976 C6798 6/8 No Yes, reduction in tacrolimus between wk 4 and 6 Foscarnet, ganciclovir 14 Renal tubulopathy Yes (U97 mutation) No CR Sustained CR after second infusion 
3762 C6808 5/8 CMV retinitis No None Unable to tolerate Poor graft function Not done Yes, ganciclovir administered for 1 wk CR Sustained CR 
3967 C6823 2/8 CMV colitis (diarrhea) No Foscarnet 211 AKI Yes (U97 mutation) No PR Died of renal failure and AdV infection 
4091 C6790 5/8 No No Foscarnet, cidofovir, leflunomide 29 AKI Not done No CR Died of renal failure 
4115 C6834 5/8 No No Foscarnet 24 AKI Not done No CR Sustained CR 
4170 C6790 3/8 No No Ganciclovir, foscarnet 42 Pancreatitis No No CR Sustained CR 
4134 C6798 5/8 CMV colitis (diarrhea) No Foscarnet, ganciclovir 17 No Not done No PR Sustained CR 
4201 C6814 3/8 No Yes, tacrolimus taper initiated before VST infusion Foscarnet, ganciclovir 41 No No No PR Sustained CR after third infusion 
Patient ID no.Infused VSTsHLA matchingViral diseaseReduction in immuno-suppressionPrior antiviral(s)Duration prior antiviral therapyAntiviral drug intoleranceCMV resistanceChange in antiviral post-VSTResponse by 6 wkOverall outcome
3910 C6790 2/8 No No Ganciclovir 17 No No No CR Sustained CR 
3944 C6798 4/8 No No Leflunomide 94 AKI, cytopenia Yes No CR Sustained CR 
3976 C6798 6/8 No Yes, reduction in tacrolimus between wk 4 and 6 Foscarnet, ganciclovir 14 Renal tubulopathy Yes (U97 mutation) No CR Sustained CR after second infusion 
3762 C6808 5/8 CMV retinitis No None Unable to tolerate Poor graft function Not done Yes, ganciclovir administered for 1 wk CR Sustained CR 
3967 C6823 2/8 CMV colitis (diarrhea) No Foscarnet 211 AKI Yes (U97 mutation) No PR Died of renal failure and AdV infection 
4091 C6790 5/8 No No Foscarnet, cidofovir, leflunomide 29 AKI Not done No CR Died of renal failure 
4115 C6834 5/8 No No Foscarnet 24 AKI Not done No CR Sustained CR 
4170 C6790 3/8 No No Ganciclovir, foscarnet 42 Pancreatitis No No CR Sustained CR 
4134 C6798 5/8 CMV colitis (diarrhea) No Foscarnet, ganciclovir 17 No Not done No PR Sustained CR 
4201 C6814 3/8 No Yes, tacrolimus taper initiated before VST infusion Foscarnet, ganciclovir 41 No No No PR Sustained CR after third infusion 

AdV, adenovirus; AKI, acute kidney injury; PR, partial response.

Close Modal

or Create an Account

Close Modal
Close Modal